US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.8441 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Expert Ratings for Mainz Biomed ↗
 
Via Benzinga
News headline image
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
News headline image
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  During Wednesday's trading, 123 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday's session saw 286 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Mainz Biomed Provides Full Year 2022 Financial Results
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 99 companies made new 52-week lows. 
Via Benzinga
News headline image
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
From Mainz BioMed NV
Via GlobeNewswire
Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates ($MYNZ)
Via AB Newswire
Mainz Biomed ($MYNZ) Inks Accretive Partnership To Expand Marketing Reach Of ColoAlert Diagnostic, Analysts Model For Over 72% Upside ($MYNZ)
Via AB Newswire
News headline image
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network. 
From Mainz BioMed NV
Via GlobeNewswire
In Focus: Mainz Biomed Nears Multiple Data Set Releases Expected To Fuel 2023 Growth ($MYNZ)
Via AB Newswire
News headline image
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed In Focus Ahead Of Two Data-Set Releases In 1H/2023 ($MYNZ)
Via AB Newswire
News headline image
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
Virtual Fireside Chat via Paltalk Platform 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s Milestones Reached In 2022 Can Be Catalysts In 1/H 2023…Here’s Why ($MYNZ)
Via AB Newswire
News headline image
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
Continued roll-out in Europe with onboarding of new lab partners 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023 ↗
 
Via Benzinga
News headline image
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Patient Access Initiative Addresses €1 Billion Annual Market in Germany 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides Year-End 2022 Corporate Review
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket ↗
Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday. 
Via Benzinga
News headline image
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >